Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States.
Show moreShow less
Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities.
The company was founded in 2011 and is headquartered in Vancouver, Washington.
Quality Score breakdown
Overall quality30/100
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Profitability0
How much profit the company makes from its sales and capital
Quality Growth29
Are margins and returns getting better?
Cashflow7
Do the profits arrive as real cash?
Financial strength83
Debt, balance sheet and risk of trouble
Investment67
Does it invest with discipline instead of growing at any price?
Low Volatility0
How calm the share price moves, does not count
Price momentum89
Price momentum of the last 3 to 12 months, does not count
In the last 6 months, 2 officers or directors bought shares worth $349,614, most recently on Jun 30, 2026. Buying cluster
BuyMary T SzelaDirector12,900 shares at $11.54$148,866Jun 30, 2026
BuyMenelas N PangalosDirector2× since Feb 27, 2026: 112,548 shares, avg. $3.61$406,508May 13, 2026
BuyAndreas BuschChief Innovation Officer100,000 shares at $2.29$229,000Mar 12, 2026
SaleZachariah JonassonCFO / CBO17,496 shares at $2.99$52,313Feb 2, 2026
SaleSean McClainChief Executive Officer, Director26,761 shares at $2.99$80,015Feb 2, 2026
BuyFrans Van HoutenDirector40,000 shares at $3.72$148,800Dec 5, 2025
Plus 13 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−38.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−21.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.1%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.2%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−278.3% (2020) → −4,454.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
News mood ⓘNews mood, the average tone of recent news (95 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score30 · Bottom 25%
Profitability
Return on assets−53.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−46.4% · Bottom 25%
Balance sheet
Debt / equity0.01× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
Absci Corp has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Absci Corp (ABSI)?
Absci Corp reported trailing-twelve-month revenue of about $1.6M (latest available figure, as of Nov 6, 2026).
How solid is the balance sheet of Absci Corp (ABSI)?
Balance-sheet figures for Absci Corp (as of Nov 6, 2026): return on equity −57.7%, debt of 0.01 per unit of equity. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
Which stocks are comparable to Absci Corp?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
What is the share price of Absci Corp (ABSI)?
The closing price on Nov 6, 2026 was $10.17. We carry closing prices from our data provider, not a live tick.
Key figures of Absci Corp
How large is the market capitalisation of Absci Corp (ABSI)?
The market capitalisation of Absci Corp is $1.8B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Absci Corp (ABSI)?
Earnings per share at Absci Corp are $−0.7900. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Absci Corp (ABSI)?
The return on equity (ROE) of Absci Corp is −57.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Absci Corp (ABSI)?
On an EBIT basis the return on assets of Absci Corp is −42.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Absci Corp (ABSI)?
The operating margin of Absci Corp is −10,742% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Absci Corp (ABSI)?
Revenue at Absci Corp is growing −46.4% versus a year earlier (3y avg −21.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Absci Corp (ABSI) generate?
The free cash flow of Absci Corp is −$94.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Absci Corp (ABSI) hold?
Absci Corp holds more cash than debt, $14.7M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Absci Corp in the live analysis
One click puts Absci Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 6, 2026